Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation
Gabriel N. Mannis(Stanford University), Aaron C. Logan(University of California, San Francisco), Peter H. Sayre(Immune Tolerance Network), Weiyun Z. Ai(City College of San Francisco), Lloyd E. Damon(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Rebecca L. Olin(University of California, San Francisco), Thomas Martin(University of California, San Francisco), Jimmy J. Hwang(University of California, San Francisco), Karin Gaensler(University of California, San Francisco), Katherine A. Kong, Malek Faham, Jeffrey L. Wolf(City College of San Francisco)
Cited by 23
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782